Innovation often accelerates faster than markets expect. Just a decade ago, autonomous vehicles seemed distant, genetic medicine remained largely theoretical, and launching satellites required government-wide budgets. However, technological progress has a way of surprising even the most optimistic observers.

Today’s autonomous delivery robots navigate city sidewalks with remarkable precision. First CRISPR gene-editing therapy cures previously incurable diseases. Private companies launch satellites every week for a fraction of historical costs. Now, these technologies are not only viable: they are creating businesses worth billions of dollars.

Image source: Getty Images.

Here’s why three companies leading these revolutions deserve your attention right now.

Robots are transforming urban delivery

Serving robotics (NASDAQ:SERV) is leading the autonomous delivery revolution with Level 4 curbside robots that are redefining last-mile logistics. Their autonomous fleet navigates urban environments while delivering food and packages for just $1 per delivery, a fraction of the human costs of couriering. In a market exceeding $230 billion, this significant cost advantage positions Serve for significant growth.

The company’s deployment of 2,000 robots by 2025 is just the beginning. Pioneering partnership with Wing Aviation will combine ground robots and aerial drones to extend delivery reach, while new revenue streams from mobile advertising and technology licensing could accelerate growth as autonomous delivery transforms logistics urban. For investors seeking early exposure to autonomous technology, Serve offers a rare combination of proven technology and a clear path to profitability.

Revolutionary engineering remedies

CRISPR therapeutics (NASDAQ:CRSP) has transformed science fiction into medical reality thanks to its gene editing platform. Their breakthrough therapy Casgevy, recently approved for devastating blood disorders, represents the first-ever approved CRISPR treatment. With over $2 billion in liquidity at the end of the most recent quarter and 35 activated global treatment centers, CRISPR Therapeutics is commercializing a new era in medicine.

The company’s ambitions extend well beyond blood diseases. Their pipeline targets previously “incurable” diseases like cancer, diabetes and heart disease. This broad-platform approach positions CRISPR Therapeutics to potentially revolutionize treatment in several multi-billion dollar markets as genetic medicine enters its golden age. Early investors have a unique opportunity to back the pioneer of a technology that could transform modern medicine.

Launch of the commercial space age

As SpaceX’s closest competitor in the field of small satellite launches, Rocket Lab United States (NASDAQ:RKLB) successfully completed 50 Electron rocket missions, a milestone achieved faster than any commercial rocket in history. With record revenue of $106 million in the second quarter of 2024 and robust growth in launch services and space systems, Rocket Lab USA is translating its technical superiority into commercial success.

Recent dynamics paint a compelling growth scenario. The company has secured 17 new launch contracts in 2024, while the next Neutron rocket targets larger payloads. With more than $720 million in spacecraft contracts and a space economy projected to reach $1 trillion by 2030, Rocket Lab USA offers investors proven technology and rapidly growing revenues in the field. commercial space race.

A new technological frontier

Serve Robotics, CRISPR Therapeutics and Rocket Lab USA are pioneers of very different technologies with a common thread: Each could fundamentally transform billion-dollar industries. Although all three companies face significant obstacles on the path to profitability, they offer investors early access to potentially game-changing technologies.

That said, these three stocks are inherently high-risk investments. But for investors willing to accept volatility, they represent three distinct ways to invest in technologies that could reshape how we deliver goods, treat disease and access space in the coming decade, generating potentially life-changing gains for the first shareholders.

Don’t miss this second chance and a potentially lucrative opportunity

Have you ever felt like you missed the boat by buying the best performing stocks? Then you will want to hear this.

On rare occasions, our team of expert analysts issues a “Doubled” actions recommendation for businesses that they believe are on the verge of collapse. If you’re worried that you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Amazon: If you invested $1,000 when we doubled down in 2010, you would have $22,292!*

• Apple: If you invested $1,000 when we doubled down in 2008, you would have $42,169!*

• Netflix: If you invested $1,000 when we doubled down in 2004, you would have $407,758!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

See 3 “Double Down” Stocks »

*Stock Advisor returns as of November 4, 2024

George Budwell holds positions at CRISPR Therapeutics and Rocket Lab USA. The Motley Fool ranks and recommends CRISPR Therapeutics and Serve Robotics. The Motley Fool recommends Rocket Lab USA. The Motley Fool has a disclosure policy.